Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이민형 | - |
dc.date.accessioned | 2018-03-01T01:48:13Z | - |
dc.date.available | 2018-03-01T01:48:13Z | - |
dc.date.issued | 2012-08 | - |
dc.identifier.citation | Journal of controlled release,Vol.162,No.1 [2012],p9-18 | en_US |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | http://www.sciencedirect.com/science/article/pii/S0168365912005032?via%3Dihub | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/41393 | - |
dc.description.abstract | Exendin-4, glucagon-like peptide 1 (GLP-1) receptor agonist, is an exocrine hormone, which has potent insulinotropic actions similar to GLP-1 such as stimulating insulin biosynthesis, facilitating glucose concentration dependent insulin secretion, slowing gastric emptying, reducing food intake and stimulating beta-cell proliferation. Exendin-4, also, has a longer half-life than GLP-1, due to its resistance to degradation by dipeptidyl peptidase-IV (DPP-IV). In spite of its many advantages as a therapeutic agent for diabetes, its clinical application is still restricted. Thus, to improve the activity of exendin-4 in vivo, gene therapy system was developed as an alternative method. An exendin-4 expression system was constructed using the two-step transcription amplification (TSTA) system, which is composed of p beta-Gal4-p65 and pUAS-SP-exendin-4 with combining the advantages of signal peptide (SP) in order to facilitate its secretion in ectopic cells or tissue. Arginine-grafted cyctaminebisacrylamide-diaminohexane polymer (ABP) was used as a gene carrier. Increased expression of exendin-4, glucose dependent insulin secretion in NIT-1 insulinoma cells, and high insulin expression in the presence of DPP-IV were evaluated in vitro after delivery of ABP/TSTA-SP-exendin-4. Blood glucose levels in diabetic mice were decreased dramatically from the third day for experimental period after single intravenous administration with ABP/TSTA-SP-exendin-4. The highest insulinotropic effect of exendin-4 was also observed in the ABP/TSTA/SP-exendin-4-treated mice groups, compared with the others groups from the 3rd day after injection. TSTA exendin-4 expression system with SP and ABP polymer has a potential gene therapy for the treatment of type 2 diabetes. (c) 2012 Elsevier B.V. All rights reserved. | en_US |
dc.description.sponsorship | This work was supported by NIH DK077703 and WCU 200900000000024, the Ministry of Education, Science and Technology, Korea (S-W Kim), and by the International Exchange Program for University Researchers 013-2011-1-E00060, National Research Foundation of Korea, Korea (M-H Lee). | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Science B.V., Amsterdam | en_US |
dc.subject | Diabetes | en_US |
dc.subject | Exendin-4 polyplex | en_US |
dc.subject | TSTA system | en_US |
dc.subject | Gene delivery | en_US |
dc.subject | GLUCAGON-LIKE PEPTIDE-1 | en_US |
dc.subject | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | en_US |
dc.subject | IN-VIVO | en_US |
dc.subject | RECEPTOR AGONISTS | en_US |
dc.subject | INCRETIN MIMETICS | en_US |
dc.subject | THERAPY | en_US |
dc.subject | APOPTOSIS | en_US |
dc.subject | GLP-1 | en_US |
dc.title | Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model | en_US |
dc.type | Article | en_US |
dc.relation.no | 1 | - |
dc.relation.volume | 162 | - |
dc.identifier.doi | 10.1016/j.jconrel.2012.06.010 | - |
dc.relation.page | 9-18 | - |
dc.relation.journal | JOURNAL OF CONTROLLED RELEASE | - |
dc.contributor.googleauthor | Kim, Pyung-Hwan | - |
dc.contributor.googleauthor | Lee, Minhyung | - |
dc.contributor.googleauthor | Kim, Sung-Wan | - |
dc.relation.code | 2012204927 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | minhyung | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.